上海復旦(01385.HK)股東上海政本1,280萬股被司法標記
上海復旦(01385.HK)公布,收到持股5.24%股東上海政本及其一致行動人上海年錦通知,其所持1,280萬股被司法標記。
公司指,上述司法標記股份涉及兩項合同糾紛,首項案件涉及300萬股被司法標記,債權額及執行費用1.21億元人民幣,案件正在審理過程中。而另一項案件中,受影響的股份涉980萬股,債權額及執行費用3.2億元人民幣,上海政本尚未收到法院送達的起訴資料。案件具體情況尚待法院送達起訴資料後進一步明確。
集團續表示,相關股份被司法凍結或司法標記,不會導致公司無實際控制人的情況發生變化,亦不會對公司日常營運與管理造成影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.